Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.

Axelrod M, Gordon VL, Conaway M, Tarcsafalvi A, Neitzke DJ, Gioeli D, Weber MJ.

Oncotarget. 2013 Apr;4(4):622-35.

PMID:
23599172
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackey A, Weber MJ, Gioeli D.

Mol Cancer Ther. 2012 Nov;11(11):2505-15. doi: 10.1158/1535-7163.MCT-12-0461. Epub 2012 Sep 7.

PMID:
22962324
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.

Xu C, Li X, Li T, Wang X, Yang Y, Xiao L, Shen H.

Asian Pac J Cancer Prev. 2011;12(11):2951-7.

PMID:
22393970
[PubMed - indexed for MEDLINE]
Free Article
4.

Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.

Ketola K, Kallioniemi O, Iljin K.

PLoS One. 2012;7(12):e51470. doi: 10.1371/journal.pone.0051470. Epub 2012 Dec 12.

PMID:
23251544
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.

West NW, Garcia-Vargas A, Chalfant CE, Park MA.

BMC Cancer. 2013 May 24;13:256. doi: 10.1186/1471-2407-13-256.

PMID:
23706161
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.

Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.

PMID:
22407832
[PubMed - indexed for MEDLINE]
Free Article
7.

Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM.

Int J Cancer. 2013 Feb 1;132(3):E149-57. doi: 10.1002/ijc.27781. Epub 2012 Sep 28.

PMID:
22948716
[PubMed - indexed for MEDLINE]
8.

A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T.

Mol Cancer Ther. 2010 Dec;9(12):3322-9. doi: 10.1158/1535-7163.MCT-10-0197. Epub 2010 Oct 1.

PMID:
20889729
[PubMed - indexed for MEDLINE]
Free Article
9.

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.

Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK.

Clin Cancer Res. 2004 Aug 1;10(15):5242-52.

PMID:
15297428
[PubMed - indexed for MEDLINE]
Free Article
10.

Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.

Budman DR, Calabro A.

Anticancer Drugs. 2004 Oct;15(9):877-81.

PMID:
15457128
[PubMed - indexed for MEDLINE]
11.

Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.

Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.

PLoS One. 2013 Jun 20;8(6):e66589. doi: 10.1371/journal.pone.0066589. Print 2013.

PMID:
23818948
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.

Sooman L, Ekman S, Andersson C, Kultima HG, Isaksson A, Johansson F, Bergqvist M, Blomquist E, Lennartsson J, Gullbo J.

Cancer Chemother Pharmacol. 2013 Aug;72(2):329-40. doi: 10.1007/s00280-013-2197-7. Epub 2013 Jun 5.

PMID:
23736154
[PubMed - indexed for MEDLINE]
13.

Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.

Li SS, Tang QL, Wang SH, Chen YH, Liu JJ, Yang XM.

Tumori. 2011 Nov-Dec;97(6):762-70. doi: 10.1700/1018.11094.

PMID:
22322844
[PubMed - indexed for MEDLINE]
14.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

PMID:
20571069
[PubMed - indexed for MEDLINE]
Free Article
15.

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.

Avramis IA, Laug WE, Sausville EA, Avramis VI.

Cancer Chemother Pharmacol. 2003 Oct;52(4):307-18. Epub 2003 Jun 25.

PMID:
12827297
[PubMed - indexed for MEDLINE]
16.

Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.

Naderi A, Chia KM, Liu J.

Breast Cancer Res. 2011 Apr 1;13(2):R36. doi: 10.1186/bcr2858.

PMID:
21457548
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.

Saiki AY, Caenepeel S, Yu D, Lofgren JA, Osgood T, Robertson R, Canon J, Su C, Jones A, Zhao X, Deshpande C, Payton M, Ledell J, Hughes PE, Oliner JD.

Oncotarget. 2014 Apr 30;5(8):2030-43.

PMID:
24810962
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.

Kandil E, Tsumagari K, Ma J, Abd Elmageed ZY, Li X, Slakey D, Mondal D, Abdel-Mageed AB.

J Surg Res. 2013 Oct;184(2):898-906. doi: 10.1016/j.jss.2013.03.052. Epub 2013 Apr 2.

PMID:
23602735
[PubMed - indexed for MEDLINE]
19.

Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.

Ping SY, Wu CL, Yu DS.

Urol Oncol. 2012 Sep;30(5):652-9. doi: 10.1016/j.urolonc.2010.07.001. Epub 2010 Sep 29.

PMID:
20884251
[PubMed - indexed for MEDLINE]
20.

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.

Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137.

PMID:
20039326
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk